MagIA diagnostics announces that Mr. Philippe Jacon will be joining its Board

Mr. Jacon will be joining MagIA diagnostics’ board after a long career in the in-vitro diagnostics business. In his previous roles, Philippe JACON was the Executive Vice President, Emerging Markets, SVP Global Access at CEPHEID from 2013 to 2023. Previously, he was CEO of the Foundation of Innovative New Diagnostics (FIND), General Director of the European Diagnostics Manufacturers Association and Worldwide President of Becton Dickinson Diagnostics Systems. Philippe JACON sat on the board of MedTech Europe between 2013 and 2022.

“Philippe brings his long experience in commercial diagnostics and medical devices to help the MagIA team, to prepare its commercial launch” said Paul Kauffmann, MagIA’s Chief Executive Officer. “Combined with his strong experience in the not-for-profit diagnostics business, Philippe is an ideal addition to the expertise of our existing board members, and we look forward to starting active collaboration with him.”

“Joining the board of MagIA diagnostics represents a great opportunity for me to support the executive team in the development and commercialization of an innovative technology,” said Philippe JACON. “The developed world as well as the low and middle-income countries need new diagnostics solutions to adapt to a rapidly evolving ecosystem and I am convinced MagIA’s technology has the potential to be one of those.”

About MagIA diagnostics:

Since its inception in 2017, MagIA is focusing its activity on developing a nomad and portable blood analyzer that runs between 4 and 8 tests within 12 to 18 minutes at the Point of Care. MagIA first kit dedicated to combined screening of HIV and Viral Hepatitis B and C undergoes clinical evaluation and shall be CE marked by 2025.